Welcome to StockRants, a new breed of stock market forum with a reputation system unlocking hidden features.

You are currently viewing our boards as a guest which gives you limited access to view most discussions. By joining our free investors group you will have access to post stock picks, private messages, downloads and can begin accumulating points for access to our private VIP area. StockRants is completely free so why not join our community today?

If you have any problems with the registration process or your account login, please contact us.

FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
7:00a ET April 29, 2009 (Business Wire)
Antigenics Inc. (NASDAQ: AGEN) today announced that Oncophage(R) (vitespen) has been granted orphan drug status for the treatment of glioma (brain cancer) by the US Food and Drug Administration (FDA). In March, the European Medicines Agency (EMEA) granted a similar designation for Oncophage.

"Glioma is such an aggressive and challenging cancer that when patients are diagnosed with recurrence of this life threatening disease, they rarely live beyond six months," said Andrew T. Parsa, MD, PhD, associate professor in the department of neurological surgery at the University of California, San Francisco, and lead investigator of a Phase 2 trial evaluating Oncophage in glioma. "Given the poor survival rates, the medical community needs new treatment options, and I am hopeful of the potential for Oncophage to significantly improve clinical outcomes in this patient population."

As announced in November 2008, final data from a Phase 1, investigator-sponsored trial conducted at the Brain Tumor Research Center at the University of California, San Francisco, showed that Oncophage vaccination following brain cancer surgery increased overall median survival to approximately 10.5 months, with four patients surviving beyond 12 months and one patient surviving almost 2.5 years. This is compared to a historical median survival of only 6.5 months postsurgery. Phase 2 results are expected to be presented later this year.

Orphan Drug Designation in the United States

In the United States, the Orphan Drug Act provides for the orphan drug designation, which aims to encourage the development of drugs involved in the diagnosis, prevention or treatment of a medical condition affecting fewer than 200,000 people in the country. Orphan drug designation entitles Antigenics to seven years of market exclusivity for Oncophage in the treatment of glioma patients in the event of market approval for this indication. Additional incentives for orphan drug development include tax credits related to development expenses, reduction in FDA user fees and FDA assistance in clinical trial design.

About Oncophage

In April 2008, Oncophage was approved in Russia for the adjuvant treatment of kidney cancer patients at intermediate-risk for disease recurrence. In October 2008, Antigenics submitted a marketing authorization application to the EMEA requesting conditional approval for Oncophage in earlier-stage, localized renal cell carcinoma.

Derived from each individual's tumor, Oncophage contains the 'antigenic fingerprint' of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy. Oncophage has been studied in Phase 3 clinical trials for the treatment of kidney cancer and metastatic melanoma and is currently being investigated in a Phase 2 trial in recurrent glioma.

Oncophage has also received fast track and orphan drug designations from the U.S. Food and Drug Administration for both kidney cancer and metastatic melanoma.

In April 2009, the World Vaccine Congress named Oncophage the best therapeutic vaccine.

About Brain Tumors

Glioma is the most common type of brain tumor and is currently a fatal disease impairing areas such as thinking, personality and movement. The National Cancer Institute estimates that about 19,000 cases are diagnosed every year in the United States and, according to historical estimates, the median survival of patients with previously treated glioma is typically three to six months.

Yeah - its gone up pre trade but think it has more legs. Everyone is watching DNDN so you can double down. I am now IN this stock from last time.

__________________
Always do your own research and make up your own mind on any stock. Top investors follow themselves, sheep get slaughtered. Any tip, suggestion or comment posted by me is simply a suggestion / prompt for you to make up your own mind. No liability will be accepted. Its not a professional view, its a suggestion. Shares go up and down. Always spread your investments, always set your stops both up and down. If shorting or Futures investing, know what your doing. You cant beat the sharks, but you can swim on their back. Trade lucky.

They put through 0.715 – this is after pre trade – sold in a instant for profits (leaving my old holding since the spike, post Mendys original tip)

Guys get stuck in – day trade glory, its like up and down 5 – 10% every few seconds.

I think I got the absolute bottom (thus far for the day!!!))

Made 15% in around 40 seconds..................... ha hahaha!!!

__________________
Always do your own research and make up your own mind on any stock. Top investors follow themselves, sheep get slaughtered. Any tip, suggestion or comment posted by me is simply a suggestion / prompt for you to make up your own mind. No liability will be accepted. Its not a professional view, its a suggestion. Shares go up and down. Always spread your investments, always set your stops both up and down. If shorting or Futures investing, know what your doing. You cant beat the sharks, but you can swim on their back. Trade lucky.

Mate - have you sold already! I was literally in it for a few minutes. Sweet!
(long position still in)

Mendy werent you holding this from a tiny sp? or was it another? thought it was you and Etineenggeer

__________________
Always do your own research and make up your own mind on any stock. Top investors follow themselves, sheep get slaughtered. Any tip, suggestion or comment posted by me is simply a suggestion / prompt for you to make up your own mind. No liability will be accepted. Its not a professional view, its a suggestion. Shares go up and down. Always spread your investments, always set your stops both up and down. If shorting or Futures investing, know what your doing. You cant beat the sharks, but you can swim on their back. Trade lucky.

"Antigenics to Report First Quarter 2009 Financial Results on May 7, 2009; Conference Call to Follow"

Mendy - whats your thoughts - especially as its dipped since the spike. I sold a chuck hence ready to go back in, do you think it will lift up? or the drug news lifted it as much as its going to go for the time being. Just interested in your views here.

__________________
Always do your own research and make up your own mind on any stock. Top investors follow themselves, sheep get slaughtered. Any tip, suggestion or comment posted by me is simply a suggestion / prompt for you to make up your own mind. No liability will be accepted. Its not a professional view, its a suggestion. Shares go up and down. Always spread your investments, always set your stops both up and down. If shorting or Futures investing, know what your doing. You cant beat the sharks, but you can swim on their back. Trade lucky.